Overview
- A federal class action titled Mazzarino v. ADMA Biologics was filed in the U.S. District Court for the District of New Jersey alleging violations of the securities laws by ADMA and certain executives.
- The complaint, relying on a March 24 short‑seller report, accuses ADMA of inducing a distributor to take excess product through rebates and extended payment terms to book revenue and overstate 2025 growth.
- ADMA publicly called the short report false on March 25, and the company’s stock fell about $3.96 per share, or roughly 29%, across March 24–25 as reported by multiple firms.
- Several plaintiff‑side law firms are actively soliciting investors to move for lead‑plaintiff status and remind eligible shareholders that the deadline to seek appointment is August 10, 2026.
- Next steps include competing lead‑plaintiff motions, the court’s appointment of lead counsel, and discovery that will test the channel‑stuffing, related‑party and internal‑controls allegations which remain unproven.